SUPERNUS PHARMACEUTICALS, INC. Shareholders' Equity
SUPERNUS PHARMACEUTICALS, INC. (SUPN) had Shareholders' Equity of $1.03 billion as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-03
- 2026-06-30: Stockholders' Equity Attributable to Parent $1.03B.
- 2026-03-31: Stockholders' Equity Attributable to Parent $1.08B.
- 2025-12-31: Stockholders' Equity Attributable to Parent $1.06B.
- 2025-09-30: Stockholders' Equity Attributable to Parent $1.05B.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $1.03B 10-Q · filed 2026-08-03 | |
| 2026-03-31 | $1.08B 10-Q · filed 2026-08-03 | |
| 2025-12-31 | $1.06B 10-Q · filed 2026-08-03 | |
| 2025-09-30 | $1.05B 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $1.06B 10-Q · filed 2026-08-03 | |
| 2025-03-31 | $1.03B 10-Q · filed 2026-08-03 | |
| 2024-12-31 | $1.04B 10-Q · filed 2026-08-03 | |
| 2024-09-30 | $1.01B 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $957.45M 10-Q · filed 2025-11-06 | |
| 2024-03-31 | $929.17M 10-Q · filed 2025-11-06 | |
| 2023-12-31 | $921.52M 10-K · filed 2026-03-02 | |
| 2023-09-30 | $912.19M 10-Q · filed 2024-11-04 | |
| 2023-06-30 | $919.91M 10-Q · filed 2024-11-04 | |
| 2023-03-31 | $912.15M 10-Q · filed 2024-11-04 | |
| 2022-12-31 | $886.20M 10-K · filed 2026-03-02 | |
| 2022-09-30 | $852.80M 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $841.43M 10-Q · filed 2023-11-08 | |
| 2022-03-31 | $828.45M 10-Q · filed 2023-11-08 | |
| 2021-12-31 | $815.85M 10-K · filed 2025-02-25 | |
| 2021-09-30 | $810.47M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $785.58M 10-Q · filed 2022-11-09 | |
| 2021-03-31 | $754.44M 10-Q · filed 2022-11-09 | |
| 2020-12-31 | $744.86M 10-K · filed 2023-03-09 | |
| 2020-09-30 | $708.88M 10-Q · filed 2021-11-05 | |
| 2020-06-30 | $665.97M 10-Q · filed 2021-11-05 | |
| 2020-03-31 | $613.38M 10-Q · filed 2021-11-05 | |
| 2019-12-31 | $595.43M 10-K · filed 2023-03-09 | |
| 2019-09-30 | $557.26M 10-Q · filed 2020-11-06 | |
| 2019-06-30 | $522.90M 10-Q · filed 2020-11-06 | |
| 2019-03-31 | $480.02M 10-Q · filed 2020-11-06 | |
| 2018-12-31 | $453.02M 10-K · filed 2022-04-13 | |
| 2018-09-30 | $421.94M 10-Q · filed 2019-11-08 | |
| 2018-06-30 | $390.49M 10-Q · filed 2019-11-08 | |
| 2018-03-31 | $351.87M 10-Q · filed 2019-11-08 | |
| 2017-12-31 | $267.48M 10-K · filed 2021-03-08 | |
| 2017-09-30 | $251.66M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $229.40M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $206.06M 10-Q · filed 2017-05-09 | |
| 2016-12-31 | $191.75M 10-K · filed 2020-02-28 | |
| 2016-09-30 | $173.37M 10-Q · filed 2017-01-20 | |
| 2016-06-30 | $110.22M 10-Q/A · filed 2017-01-23 | $141.02M 10-Q · filed 2016-08-05 |
| 2016-03-31 | $97.11M 10-Q/A · filed 2017-01-20 | $128.14M 10-Q · filed 2016-05-10 |
| 2015-12-31 | $88.01M 10-K · filed 2019-03-01 | $118.88M 10-K · filed 2016-03-09 |
| 2015-09-30 | $78.59M 10-Q/A · filed 2017-01-20 | $109.44M 10-Q · filed 2015-11-09 |
| 2015-06-30 | $71.82M 10-Q/A · filed 2017-01-23 | $102.36M 10-Q · filed 2015-08-07 |
| 2015-03-31 | $63.75M 10-Q/A · filed 2017-01-20 | $94.58M 10-Q · filed 2015-05-06 |
| 2014-12-31 | $40.70M 10-K · filed 2018-03-01 | $71.35M 10-K · filed 2015-03-12 |
| 2014-09-30 | $35.99M 10-Q/A · filed 2017-01-20 | $66.12M 10-Q · filed 2014-11-12 |
| 2014-06-30 | $33.37M 10-Q · filed 2014-08-12 | |
| 2014-03-31 | $29.01M 10-Q · filed 2014-05-13 | |
| 2013-12-31 | $33.46M 10-K · filed 2017-03-16 | |
| 2013-09-30 | $12.45M 10-Q · filed 2013-11-13 | |
| 2013-06-30 | $35.89M 10-Q · filed 2013-08-14 | |
| 2013-03-31 | $41.27M 10-Q · filed 2013-05-15 | |
| 2012-12-31 | $57.57M 10-K/A · filed 2017-01-20 | |
| 2012-09-30 | $24.63M 10-Q · filed 2012-11-02 | |
| 2012-06-30 | $37.98M 10-Q · filed 2012-08-13 | |
| 2012-03-31 | $274.00K 10-Q · filed 2012-06-08 | |
| 2011-12-31 | $9.44M 10-K · filed 2015-03-12 | |
| 2010-12-31 | -$44.32M 10-K · filed 2014-03-21 | |
| 2009-12-31 | -$6.16M 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |